Lilly opens state-of-the-art research and development center in the Boston Seaport
Eli Lilly and Company (NYSE: LLY) has opened the Lilly Seaport Innovation Center (LSC) in the Boston Seaport, a state-of-the-art research and development facility focused on advancing RNA and DNA-based therapies. The 346,000 square foot, 12-story building will house approximately 500 Lilly scientists and researchers, plus 200 people from Lilly Gateway Labs' companies. LSC serves as the central hub for Lilly's genetic medicines efforts and includes the first East Coast Lilly Gateway Labs location.
The facility aims to discover new drug targets for creating life-changing medicines in areas such as diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. This expansion reinforces Lilly's commitment to the Boston area and fosters collaboration with leading institutions to accelerate the development of novel medicines.
Eli Lilly and Company (NYSE: LLY) ha inaugurato il Lilly Seaport Innovation Center (LSC) nel Boston Seaport, una struttura all'avanguardia dedicata alla ricerca e allo sviluppo, focalizzata sull'avanzamento delle terapie a base di RNA e DNA. L'edificio di 346.000 piedi quadrati, con 12 piani, ospiterà circa 500 scienziati e ricercatori di Lilly, oltre a 200 persone delle aziende di Lilly Gateway Labs. LSC funge da punto centrale per gli sforzi di Lilly nelle medicine genetiche e include la prima sede di Lilly Gateway Labs sulla costa est.
La struttura mira a scoprire nuovi bersagli farmacologici per la creazione di medicinali in grado di cambiare la vita in aree come diabete, obesità, malattie cardiovascolari, neurodegenerazione e dolore cronico. Questa espansione rinforza l'impegno di Lilly per l'area di Boston e promuove la collaborazione con istituzioni leader per accelerare lo sviluppo di nuovi farmaci.
Eli Lilly and Company (NYSE: LLY) ha inaugurado el Lilly Seaport Innovation Center (LSC) en el Boston Seaport, una instalación de investigación y desarrollo de última generación centrada en el avance de terapias basadas en RNA y ADN. El edificio de 346,000 pies cuadrados y 12 pisos albergará aproximadamente a 500 científicos e investigadores de Lilly, además de 200 personas de las empresas de Lilly Gateway Labs. LSC sirve como el centro principal de los esfuerzos de Lilly en medicamentos genéticos e incluye la primera ubicación de Lilly Gateway Labs en la costa este.
La instalación tiene como objetivo descubrir nuevos objetivos de medicamentos para crear tratamientos que cambien la vida en áreas como diabetes, obesidad, enfermedades cardiovasculares, neurodegeneración y dolor crónico. Esta expansión refuerza el compromiso de Lilly con el área de Boston y fomenta la colaboración con instituciones líderes para acelerar el desarrollo de nuevos medicamentos.
엘리 릴리 앤드 컴퍼니(Eli Lilly and Company)(NYSE: LLY)가 보스턴 시포트에 릴리 시포트 혁신 센터 (LSC)를 개관했습니다. 이 최첨단 연구개발 시설은 RNA 및 DNA 기반 치료법의 발전에 중점을 두고 있습니다. 34만6천 평방피트 규모의 12층 건물에는 약 500명의 릴리 과학자 및 연구원과 릴리 게이트웨이 연구소의 200명이 함께 근무할 예정입니다. LSC는 릴리의 유전자 의약품 연구를 위한 중심 허브 역할을 하며, 동부 해안 최초의 릴리 게이트웨이 연구소 위치를 포함합니다.
이 시설의 목표는 당뇨병, 비만, 심혈관 질환, 신경퇴행 및 만성 통증 등의 분야에서 삶을 변화시키는 의약품을 개발하기 위한 새로운 약물 표적을 발견하는 것입니다. 이번 확장은 보스턴 지역에 대한 릴리의 헌신을 강화하고, 새로운 의약품 개발을 가속화하기 위해 선도 기관과의 협력을 촉진합니다.
Eli Lilly and Company (NYSE: LLY) a ouvert le Lilly Seaport Innovation Center (LSC) dans le Boston Seaport, un centre de recherche et développement à la pointe de la technologie axé sur l'avancement des thérapies basées sur l'ARN et l'ADN. Bâtiment de 32 000 pieds carrés et de 12 étages, il accueillera environ 500 scientifiques et chercheurs de Lilly, ainsi que 200 personnes des entreprises Lilly Gateway Labs. LSC sert de plaque tournante centrale pour les efforts de Lilly en matière de médicaments génétiques et comprend le premier emplacement de Lilly Gateway Labs sur la côte est.
Cette installation vise à découvrir de nouvelles cibles médicamenteuses pour créer des médicaments qui changent la vie dans des domaines tels que le diabète, l'obésité, les maladies cardiovasculaires, la neurodégénérescence et la douleur chronique. Cette expansion renforce l'engagement de Lilly envers la région de Boston et favorise la collaboration avec des institutions de premier plan pour accélérer le développement de nouveaux médicaments.
Eli Lilly and Company (NYSE: LLY) hat das Lilly Seaport Innovation Center (LSC) im Boston Seaport eröffnet, ein hochmodernes Forschungs- und Entwicklungszentrum, das sich auf die Förderung von RNA- und DNA-basierten Therapien konzentriert. Das 32.000 Quadratmeter große, 12-stöckige Gebäude wird rund 500 Wissenschaftler und Forscher von Lilly sowie 200 Mitarbeiter von den Unternehmen der Lilly Gateway Labs beherbergen. LSC dient als zentrales Drehkreuz für Lillys Bemühungen im Bereich genetische Medikamente und umfasst den ersten Standort von Lilly Gateway Labs an der Ostküste.
Die Einrichtung hat das Ziel, neue Arzneimittelziele zur Schaffung von lebensverändernden Medikamenten in Bereichen wie Diabetes, Fettleibigkeit, Herz-Kreislauf-Erkrankungen, Neurodegeneration und chronischen Schmerz zu entdecken. Diese Expansion verstärkt Lillys Engagement für die Region Boston und fördert die Zusammenarbeit mit führenden Institutionen, um die Entwicklung neuartiger Medikamente zu beschleunigen.
- Opening of a large 346,000 square foot R&D facility in the Boston Seaport
- Expansion of research capabilities in RNA and DNA-based therapies
- Accommodation for 500 Lilly scientists and researchers, plus 200 from Gateway Labs companies
- Establishment of the first East Coast Lilly Gateway Labs location
- None.
Insights
Lilly's new Seaport Innovation Center in Boston represents a significant investment in the company's future, particularly in the rapidly growing field of genetic medicines. This 346,000 square foot facility demonstrates Lilly's commitment to expanding its research capabilities and talent pool.
The center's focus on RNA and DNA-based therapies aligns with industry trends towards personalized medicine and targeted treatments. This strategic move could potentially lead to breakthrough therapies in high-value areas like diabetes, obesity and neurodegeneration, potentially boosting Lilly's pipeline and future revenue streams.
The inclusion of Lilly Gateway Labs also suggests a focus on fostering innovation through collaboration with startups and external partners, which could accelerate drug discovery and development processes. While the immediate financial impact may be , this investment positions Lilly for long-term growth in cutting-edge therapeutic areas.
Lilly's new Seaport Innovation Center signifies a strategic shift towards genetic medicine, a rapidly growing sector in biotech. By establishing a presence in Boston's biotech hub, Lilly is positioning itself to attract top talent and foster collaborations with leading academic institutions and biotech startups.
The focus on RNA and DNA-based therapies is particularly noteworthy, as these modalities have shown promise in treating previously undruggable targets. This move could potentially accelerate Lilly's drug discovery efforts and expand its pipeline in key therapeutic areas.
The Lilly Gateway Labs concept is an innovative approach to R&D, potentially allowing Lilly to tap into external innovation while maintaining control over intellectual property. This model could prove important in maintaining a competitive edge in the fast-paced biotech landscape.
The opening of Lilly's Seaport Innovation Center in Boston's rapidly expanding Seaport district is a significant development for the local real estate market. The 346,000 square foot, 12-story building developed by Alexandria Real Estate Equities (ARE) underscores the continued demand for high-quality life sciences real estate in prime biotech hubs.
This investment by Lilly validates ARE's strategy of developing specialized facilities for life sciences companies. It also highlights the Seaport district's growing appeal as a biotech cluster, potentially driving up property values and attracting further investment in the area.
The facility's capacity to accommodate 700 people (500 Lilly employees plus 200 from Gateway Labs companies) will likely have a positive impact on the local economy, potentially boosting demand for nearby commercial and residential real estate.
Lilly Seaport Innovation Center (LSC) serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Gateway Labs
New 346,000 square foot facility will accommodate approximately 500 Lilly scientists and researchers, in addition to 200 people from Lilly Gateway Labs' companies
"The opening of LSC expands upon Lilly's long-standing presence in the
LSC occupies 346,000 square feet in a 12-story building, developed and operated by Alexandria Real Estate Equities, Inc. (ARE), in the rapidly expanding Seaport district of
About Lilly Gateway Labs
Lilly Gateway Labs is a best-in-class innovation hub that connects promising, early-stage biotechs to the power of Lilly's expertise. By fostering scientific breakthroughs and helping biotechs remove hurdles, we help companies speed the development of life-changing medicines for patients around the world. We apply a one-of-a-kind, hands-on approach to scientific engagement, offering not just state-of-the-art wet lab spaces and strong operational support, but also curating programs to help biotechs avoid common pitfalls. Our flexible model ensures companies can execute on their scientific vision while maintaining full ownership of their intellectual property. Since opening in December 2019, Gateway Labs in
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly Seaport Innovation Center (LSC) and reflects Lilly's current beliefs and expectations. However, there can be no assurance that LSC or the science being conducted there will achieve Lilly's objectives or that Lilly will execute its strategy as planned. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: Stefanie Prodouz; stefanie.prodouz@lilly.com; +1-317-287-9899 (Media)
Joe Fletcher; jfletcher@lilly.com; +1-317-296-2884 (Investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-opens-state-of-the-art-research-and-development-center-in-the-boston-seaport-302219992.html
SOURCE Eli Lilly and Company
FAQ
What is the Lilly Seaport Innovation Center (LSC) and when did it open?
How many employees will the new Lilly Seaport Innovation Center accommodate?
What are the main research areas for Eli Lilly's (LLY) new Seaport Innovation Center?
What is the size of Eli Lilly's (LLY) new research facility in Boston?
